The global T-cell acute lymphoblastic leukemia market is prognosticated dwell on a decent CAGR of 8.4% within the forecast period from 2019 to 2026. In 2018, the T-cell acute lymphoblastic leukemia market was valued around worth US$ 339.5 mn. The global T-cell acute lymphoblastic leukemia market is driven by rise in prevalence of T-cell acute lymphoblastic leukemia. The global market is projected to grow at a rapid pace during the forecast period. This is attributed to increase in cancer awareness programs and strong product pipeline.
This report analyzes the current and future scenario of the global T-cell acute lymphoblastic leukemia market. Increase in patient population with T-cell acute lymphoblastic leukemia, growth of the pharmaceutical industry, improvement in health care infrastructure, and increase in the number of clinical trials are projected to be major drivers of the global market during the forecast period.
The global T-cell acute lymphoblastic leukemia market report comprises an elaborate executive summary, which includes a snapshot that provides information about various segments of the market. It also provides information and data analysis of the global market with respect to the segments based on treatment type, end-user, and region. A detailed qualitative analysis of drivers and restraints of the market, and opportunities has been provided in the overview section. Additionally, the section comprises competitive matrix and company profiles along with business overview to understand the competitive landscape in the market. This section of the report also provides market attractiveness analysis by region and market share analysis by key players, thereby presenting a thorough analysis of the overall competitive scenario in the global T-cell acute lymphoblastic leukemia market.
Global T-cell Acute Lymphoblastic Leukemia Market: Key Segments
Based on treatment, the global T-cell acute lymphoblastic leukemia market has been segmented into chemotherapy, radiation therapy, bone marrow transplant, targeted therapy, and immunotherapy. The segments have been analyzed based on available drug product used during the treatment of T-cell acute lymphoblastic leukemia, cost-effectiveness, and preference for industries. In terms of end-user, the global market has been classified into hospital, clinics, and others. The market size and forecast for each of these segments have been provided for the period from 2016 to 2026, along with their respective CAGRs for the forecast period from 2019 to 2026, considering 2017 as the base year.
Global T-cell Acute Lymphoblastic Leukemia Market: Regional Outlook
In terms of region, the global T-cell acute lymphoblastic leukemia market has been segmented into North America (U.S. and Canada), Europe (U.K., Germany, France, Spain, Italy, and Rest of Europe), Asia Pacific (India, China, Japan, Australia & New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and Middle East & Africa (South Africa, GCC Countries, Israel, and Rest of Middle East & Africa). The market size and forecast for each of these regions and the mentioned countries have been provided for the period from 2016 to 2026, along with their respective CAGRs for the forecast period from 2019 to 2026, considering 2017 as the base year. The research study also covers the competitive scenario in these regions.
Companies Mentioned in Report
The report also profiles major players in the global T-cell acute lymphoblastic leukemia market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. The major players profiled in the market report include Sanofi, Pfizer, Novartis AG, F. Hoffmann-La Roche Ltd., Erytech Pharma Inc., and Celgene Corporation.
The global T-cell acute lymphoblastic leukemia market has been segmented as below:
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global T-cell Acute Lymphoblastic Leukemia Market
4. Market Overview
4.1. Introduction
4.2. Global T-cell Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, 2018–2026
4.3. Global T-cell Acute Lymphoblastic Leukemia Market Outlook
4.4. Key Industry Developments
4.5. T-cell Acute Lymphoblastic Leukemia Market: Pipeline Analysis
4.6. Nelarabine: Clinical Trial
4.7. Acute Lymphocytic Leukemia New Cases, 2017
4.8. Reimbursement Scenario for Cancer Treatment
4.9. Regulatory Guidelines for Therapeutics
5. Market Dynamics
5.1. Drivers and Restraints Snapshot Analysis
5.2. Drivers
5.3. Restraints
5.4. Opportunities
5.5. Key Trends
6. Global T-cell Acute Lymphoblastic Leukemia Market, by Treatment
6.1. Introduction
6.2. Global T-cell Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Treatment
6.3. Global T-cell Acute Lymphoblastic Leukemia Market Value Forecast, by Treatment
6.3.1. Chemotherapy
6.3.2. Radiation Therapy
6.3.3. Bone Marrow Transplant
6.3.4. Targeted Therapy
6.3.4. Immunotherapy
7. Global T-cell Acute Lymphoblastic Leukemia Market, by End-user
7.1. Key Findings
7.2. Introduction
7.3. Global T-cell Acute Lymphoblastic Leukemia Market Value Share Analysis, by End-user
7.4. Global T-cell Acute Lymphoblastic Leukemia Market Forecast, by End-user
7.5. Global T-cell Acute Lymphoblastic Leukemia Market Analysis, by End-user
7.5.1. Hospitals
7.5.2. Clinics
7.5.3. Others
7.6. Global T-cell Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by End-user
8. T-cell Acute Lymphoblastic Leukemia Market Analysis, by Region
8.1. Key Findings
8.2. Global Market Scenario
8.3. Global T-cell Acute Lymphoblastic Leukemia Market Value Share Analysis, by Region
8.4. Global T-cell Acute Lymphoblastic Leukemia Market Forecast, by Region
8.4.1. North America
8.4.2. Europe
8.4.3. Asia Pacific
8.4.4. Latin America
8.4.5. Middle East & Africa
8.5. Global T-cell Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Region
9. North America T-cell Acute Lymphoblastic Leukemia Market
9.1. Key Findings
9.2. North America T-cell Acute Lymphoblastic Leukemia Market Overview
9.3. North America T-cell Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Country
9.4. North America T-cell Acute Lymphoblastic Leukemia Market Value Forecast, by Country
9.4.1. U.S.
9.4.2. Canada
9.5. North America T-cell Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Treatment
9.6. North America T-cell Acute Lymphoblastic Leukemia Market Value Forecast, by Treatment
9.6.1. Chemotherapy
9.6.2. Radiation Therapy
9.6.3. Bone Marrow Transplant
9.6.4. Targeted Therapy
9.6.4. Immunotherapy
9.7. North America T-cell Acute Lymphoblastic Leukemia Market Value Share Analysis, by End-user
9.8. North America T-cell Acute Lymphoblastic Leukemia Market Forecast, End-user
9.8.1. Hospitals
9.8.2. Clinics
9.8.3. Others
9.9. North America T-cell Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by End-user
10. Europe T-cell Acute Lymphoblastic Leukemia Market
10.1. Key Findings
10.2. Europe T-cell Acute Lymphoblastic Leukemia Market Overview
10.3. Europe T-cell Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Country
10.4. Europe T-cell Acute Lymphoblastic Leukemia Market Value Forecast, by Country/Sub-region
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Rest of Europe
10.5. Europe T-cell Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Treatment
10.6. Europe T-cell Acute Lymphoblastic Leukemia Market Value Forecast, by Treatment
10.6.1. Chemotherapy
10.6.2. Radiation Therapy
10.6.3. Bone Marrow Transplant
10.6.4. Targeted Therapy
10.6.4. Immunotherapy
10.7. Europe T-cell Acute Lymphoblastic Leukemia Market Value Share Analysis, by End-user
10.8. Europe T-cell Acute Lymphoblastic Leukemia Market Forecast, End-user
10.8.1. Hospitals
10.8.2. Clinics
10.8.3. Others
10.9. Europe T-cell Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by End-user
11. Asia Pacific T-cell Acute Lymphoblastic Leukemia Market
11.1. Key Findings
11.2. Asia Pacific T-cell Acute Lymphoblastic Leukemia Market Overview
11.3. Asia Pacific T-cell Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Country
11.4. Asia Pacific T-cell Acute Lymphoblastic Leukemia Market Value Forecast, by Country/Sub-region
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of APAC
11.5. Asia Pacific T-cell Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Treatment
11.6. Asia Pacific T-cell Acute Lymphoblastic Leukemia Market Value Forecast, by Treatment
11.6.1. Chemotherapy
11.6.2. Radiation Therapy
11.6.3. Bone Marrow Transplant
11.6.4. Targeted Therapy
11.6.4. Immunotherapy
11.7. Asia Pacific T-cell Acute Lymphoblastic Leukemia Market Value Share Analysis, by End-user
11.8. Asia Pacific T-cell Acute Lymphoblastic Leukemia Market Forecast, End-user
11.8.1. Hospitals
11.8.2. Clinics
11.8.3. Others
11.9. Asia Pacific T-cell Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by End-user
12. Latin America T-cell Acute Lymphoblastic Leukemia Market
12.1. Key Findings
12.2. Latin America T-cell Acute Lymphoblastic Leukemia Market Overview
12.3. Latin America T-cell Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Country
12.4. Latin America T-cell Acute Lymphoblastic Leukemia Market Value Forecast, by Country/Sub-region
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of LATAM
12.5. Latin America T-cell Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Treatment
12.6. Latin America T-cell Acute Lymphoblastic Leukemia Market Value Forecast, by Treatment
12.6.1. Chemotherapy
12.6.2. Radiation Therapy
12.6.3. Bone Marrow Transplant
12.6.4. Targeted Therapy
12.6.4. Immunotherapy
12.7. Latin America T-cell Acute Lymphoblastic Leukemia Market Value Share Analysis, by End-user
12.8. Latin America T-cell Acute Lymphoblastic Leukemia Market Forecast, End-user
12.8.1. Hospitals
12.8.2. Clinics
12.8.3. Others
12.9. Latin America T-cell Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by End-user
13. Middle East & Africa T-cell Acute Lymphoblastic Leukemia Market
13.1. Key Findings
13.2. Middle East & Africa T-cell Acute Lymphoblastic Leukemia Market Overview
13.3. Middle East & Africa T-cell Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Country
13.4. Middle East & Africa T-cell Acute Lymphoblastic Leukemia Market Value Forecast, by Country/Sub-region
13.4.1. GCC Countries
13.4.2. Israel
13.4.3. South Africa
13.4.4. Rest of MEA
13.5. Middle East & Africa T-cell Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Treatment
13.6. Middle East & Africa T-cell Acute Lymphoblastic Leukemia Market Value Forecast, by Treatment
13.6.1. Chemotherapy
13.6.2. Radiation Therapy
13.6.3. Bone Marrow Transplant
13.6.4. Targeted Therapy
13.6.4. Immunotherapy
13.7. Middle East & Africa T-cell Acute Lymphoblastic Leukemia Market Value Share Analysis, by End-user
13.8. Middle East & Africa T-cell Acute Lymphoblastic Leukemia Market Forecast, End-user
13.8.1. Hospitals
13.8.2. Clinics
13.8.3. Others
13.9. Middle East & Africa T-cell Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by End-user
14. Competition Landscape
14.1. Market Player - Competition Matrix (By Tier and Size of companies)
14.2. Market Share Analysis, by Company (2017)
14.3. Company Profiles
14.3.1. Pfizer, Inc.
14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.1.2. Financial Overview
14.3.1.3. Product Portfolio
14.3.1.4. SWOT Analysis
14.3.1.5. Strategic Overview
14.3.2. Novartis AG
14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.2.2. Financial Overview
14.3.2.3. Product Portfolio
14.3.2.4. SWOT Analysis
14.3.2.5. Strategic Overview
14.3.3. F. Hoffmann-La Roche Ltd.
14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.3.2. Financial Overview
14.3.3.3. Product Portfolio
14.3.3.4. SWOT Analysis
14.3.3.5. Strategic Overview
14.3.4. Sanofi
14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.4.2. Financial Overview
14.3.4.3. Product Portfolio
14.3.4.4. SWOT Analysis
14.3.4.5. Strategic Overview
14.3.5. Erytech Pharma Inc.
14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.5.2. Financial Overview
14.3.5.3. Product Portfolio
14.3.5.4. SWOT Analysis
14.3.5.5. Strategic Overview
14.3.6. Celgene Corporation
14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.6.2. Financial Overview
14.3.6.3. Product Portfolio
14.3.6.4. SWOT Analysis
14.3.6.5. Strategic Overview
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers